Ciclosporin use during pregnancy

Drug Safety

Volumn 36, Issue 5, 2013, Pages 279-294

  Paziana, Karolina ^a   Del Monaco, Magaly ^b   Cardonick, Elyce ^c   Moritz, Michael ^d   Keller, Matthew ^e   Smith, Bruce ^e   Coscia, Lisa ^f   Armenti, Vincent ^f  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Academy Dermatology   (United States)

^c Department of Anesthesiology   (United States)

^d Lehigh Valley Health Network   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Gift of Life Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; DEXAMETHASONE; DIGOXIN; ETRETINATE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOSARTAN; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID; OXYCODONE; PLACEBO; PREDNISONE; QUININE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TICLOPIDINE; TIOGUANINE;

ADD ON THERAPY; ALOPECIA; APLASTIC ANEMIA; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; COCHRANE LIBRARY; COMORBIDITY; CROHN DISEASE; DRUG INDICATION; DRUG METABOLISM; EISENMENGER COMPLEX; ENTERITIS; FETUS OUTCOME; FIBROSING ALVEOLITIS; GRAFT REJECTION; HUMAN; HYALINE DEGENERATION; HYPERTENSION; IMMUNOADSORPTION; INCIDENCE; INFECTION; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; LIVER TRANSPLANTATION; LOW BIRTH WEIGHT; MEDICAL LITERATURE; MEDLINE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; URTICARIA;

ANIMALS; AUTOIMMUNE DISEASES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84877787075     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0034-x     Document Type: Review

References (121)

1. Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010;62(5):838-53.
2. Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19(11):1281-9.
3. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34(6):1016-21.
4. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191-211. doi: 10.2165/11595240-000000000-00000.
5. Boubouka CD, Charissi C, Kouimintzis D, et al. Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up. Acta Derm Venereol. 2011;91(1):50-4.
6. Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2 Pt 1):242-50.
7. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826-31.
8. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17(27):3204-12.
9. McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005;(2):CD000297.
10. Rohatagi S, Calic F, Harding N, et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J Clin Pharmacol. 2000;40(11):1211-26.
11. Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2):141-50.
12. Schrell C, Cursiefen C, Kruse F, et al. Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca [in German]. Klin Monbl Augenheilkd. 2012;229(5):548-53.
13. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223-43.
14. Walsh SJ, Rau LM. Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000;90(9):1463-6.
15. Borel JF. History of the discovery of cyclosporine and of its early pharmacological development. Wien Klin Wochenschr. 2002;114(12):433-7.
16. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporine A. Ann N Y Acad Sci. 1993;696:9-19.
17. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today. 1992;13(4):136-42.
18. Kahan BD. Cyclosporine. N Engl J Med. 1989;321(25):1725-38.
19. Kolars JC, Awni WM, Merion RM, et al. First pass metabolism of cyclosporine by the gut. Lancet. 1991;338(8781):1488-90.
20. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41(3):289-97.
21. Ptachcinski R, Venkataramanan R, et al. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther. 1985;38(3):296-300.
22. Choc MG. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Int J Dermatol. 1997;36(Suppl 1):1-6.
23. Meinzer A, Mueller EA, Niese D, et al. Improved oral absorption of cyclosporine by using Neoral, a microemulsion formulation. In: Lieberman R, Mukherjee A, editors. Principles of drug development in transplantation and autoimmunity. Austin: R.G. Landes; 1996. p. 259-67.
24. Saurat JH, Guérin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010;220(2):128-37.
25. Vine W, Bowers LD. Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring. Crit Rev Clin Lab Sci. 1987;25(4):275-311.
26. Ptachcinski R, Venkataramanan R, Burckart G, et al. Cyclosporine kinetics in healthy volunteers. J Clin Pharmacol. 1987;27(3):243-8.
27. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity - lest we forget. Am J Transplant. 2011;11(4):693-7.
28. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc. 1988;20(Suppl 3):759-71.
29. Feutren G, Mihatsch M. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;326(25):1654-60.
30. Feutren G, Abeywickrama K, Friend D, Von Graffenried B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol. 1990;122(Suppl 36):57-69.
31. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344(8920):423-8.
32. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39(3):464-75.
33. Dawes M, Chowienczyk P. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):819-26.
34. Thomas AG, Burrows L, Knight R, et al. The effect of pregnancy on cyclosporine levels in renal allograft patients. Obstet Gynecol. 1997;90(6):916-9.
35. Armenti V, Ahlswede K, Ahlswede B, et al. Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine treated female kidney transplant recipients. Transplantation. 1995;59(4):476-9.
36. First MR, Schroeder TJ, Monaco AP, et al. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant. 1996;10(1 Pt 1):55-9.
37. Flechner S, Katz A, Rogers A, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis. 1985;5(1):60-3.
38. Sangalli L, Bortolotti A, Passerini F, et al. Placental transfer, tissue distribution, and pharmacokinetics of cyclosporine in the pregnant rabbit. Drug Metab Dispos. 1990;18(1):102-6.
39. Lewis GJ, Lamont CA, Lee HA, et al. Successful pregnancy in a renal transplant recipient taking cyclosporin A. Br Med J (Clin Res Ed). 1983;286(6365):603.
40. Venkataramanan R, Koneru B, Wang CC, et al. Cyclosporine and its metabolites in mother and baby. Transplantation. 1988;46(3):468-9.
41. Claris O, Picaud JC, Brazier JL, et al. Pharmacokinetics of cyclosporine A in 16 newborn infants of renal or cardiac transplant mothers. Dev Pharmacol Ther. 1993;20(3-4):180-5.
42. Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am. 1997;23(1):149-67.
43. Østensen M, Lockshin M, Doria A, Valesini G, Meroni P, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology. 2008;47 Suppl 3:iii28-31.
44. Olshan AF, Mattison DR, Zwanenburg TS, International Commission for Protection against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosporine A, August 18, 1993. Mutat Res. 1994;317(2):163-73.
45. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051-5.
46. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-89.
47. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, et al. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol. 2001;97(5 Pt 2):816-8.
48. Nyberg G, Haljamäe U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65:253-5.
49. Thiru Y, Bateman D, Coulthard M. Successful breast-feeding while mother was taking cyclosporin. BMJ. 1997;315(7106):463.
50. Morton A. Cyclosporine and lactation. Nephrology. 2011;16(2):249-50.
51. Madill J, Levy G, Greig P. Pregnancy and breast-feeding while receiving cyclosporine A. In: Williams B, Sandiford-Guttenbeil D, editors. Trends in organ transplantation. New York: Springer Publishing Company; 1996. p. 108-21.
52. Moretti M, Sgro M, Johnson D, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75(12):2144-6.
53. Klintmalm G, Althoff P, Appleby G, et al. Renal function in a newborn baby delivered of a renal transplant patient taking cyclosporine. Transplantation. 1984;38(2):198-9.
54. Lamarque V, Leleu MF, Monka C, et al. Analysis of 629 pregnancy outcomes in transplant recipients treated with sandimmun. Transplant Proc. 1997;29(5):2480.
55. World Health Organization (WHO). World health report 2005: make every mother and child count. Geneva: WHO; 2005. p. 63.
56. Casey B, Lucas M, McIntire D, et al. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol. 1997;90(6):869-73.
57. ® Pregnancy Registr for Psoriasis and Rheumatoid Arthritis. Gift of Life Institute, Philadelphia, PA, 2013.
58. Gardner MO, Goldenberg RL, Cliver SP, et al. The origin and outcome of preterm twin pregnancies. Obstet Gynecol. 1995;85(4):553-7.
59. Armenti VT, Coscia LA, Constantinescu S, et al. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2009:103-22.
60. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2001:97-105.
61. Ghafari A, Sanadgol H. Pregnancy after renal transplantation: ten-year single-center experience. Transplantat Proc. 2008;40(1):251-2.
62. Al-Khader AA, Al-Ghamdi, Basri N, et al. Pregnancies in renal transplant recipients: with a focus on the maternal issues. Ann Transplant. 2004;9(3):62-4.
63. Ghanem ME, El-Baghdadi LA, Badawy AM, et al. Pregnancy outcome after renal allograft transplantation: 15 years experience. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):178-81.
64. Sreepada TK, Gupta SK, Butt KM, et al. Relationship of renal transplantation to hypertension in end-stage renal failure. Arch Intern Med. 1978;138(8):1236-41.
65. First MR, Neylan JF, Rocher LL, et al. Hypertension after renal transplantation. J Am Soc Nephrol. 1994;4(8 Suppl):S30-6.
66. Sgro MD, Barozzino T, Mirghani HM, et al. Pregnancy outcome post renal transplantation. Teratology. 2002;65(1):5-9.
67. Carmona F, Cararach V, Bedini JL, et al. Successful pregnancy after combined pancreas-kidney transplantation. Eur J Obstet Gynecol Reprod Biol. 1993;52(2):143-5.
68. Calne RY, Brons IG, Williams PF, et al. Successful pregnancy after paratopic segmental pancreas and kidney transplantation. Br Med J (Clin Res Ed). 1988;296(6638):1709.
69. Tyden G, Brattstrom C, Bjorkman U, et al. Pregnancy after combined pancreas-kidney transplantation. Diabetes. 1989;38(Suppl 1):43-5.
70. Dieperink H, Steinbruchel D, Kemp E, et al. Cataractogenic effect of cyclosporin A: a new adverse effect observed in the rat. Nephrol Dial Transplant. 1987;1(4):251-3.
71. Coscia L, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65-85.
72. Christopher V, Al-Chalabi T, Richardson PD, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transplant. 2006;12:1138-43.
73. Morini A, Spina V, Aleandri V, et al. Pregnancy after heart transplant: update and case report. Hum Reprod. 1998;13(3):749-57.
74. Shaner J, Coscia L, Constantinescu S, et al. Pregnancy after lung transplant. Prog Transplant. 2012;22(2):134-40.
75. Chinayon P, Sakornpant P. Successful pregnancy after heart-lung transplantation: a case report. Asia Oceania J Obstet Gynaecol. 1994;20(3):275-8.
76. Giudice PL, Dubourg L, Hadj-Aissa A, et al. Renal function of children exposed to cyclosporin in utero. Nephrol Dial Transplant. 2000;15(10):1575-9.
77. Al-Khader AA, Basri N, Al-Ghamd, et al. Pregnancies in renal transplant recipients: with a focus on babies. Ann Transplant. 2004;9(3):65-7.
78. Cochat P, Decramer S, Robert-Gnansia E, et al. Renal outcome of children exposed to cyclosporine in utero. Transplant Proc. 2004;36(2 Suppl):208S-10S.
79. Little BB. Immunosuppressant therapy during gestation. Semin Perinatol. 1997;21(2):143-8.
80. Rose ML, Dominguez M, Leaver N, et al. Analysis of T cell subpopulations and cyclosporine levels in the blood of two neonates born to immunosuppressed heart-lung transplant recipients. Transplantation. 1989;48(2):223-6.
81. Di Paolo S, Schena A, Morrone L, et al. Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: analysis of lymphocyte subpopulations and immunoglobulin serum levels. Transplantation. 2000;69:2049-54.
82. Stanley CW, Gottlieb R, Zager R, et al. Developmental well-being in offspring of women receiving cyclosporine post-renal transplant. Transplant Proc. 1999;31:241-2.
83. Nulman I, Sgro M, Barrera M, et al. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Pediatr Drugs. 2010;12(2):113-22.
84. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324(5):277-84.
85. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44(4):643-51.
86. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2(1):41-7.
87. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicenter study. Br J Dermatol. 1997;136(4):527-30.
88. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, Leon-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporine (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study: the PISCES study group. Br J Dermatol. 1999;141(2):283-91.
89. Raddadi AA, Damahoury ZB. Cyclosporine and pregnancy. Br J Dermatol. 1999;140(6):1197-8.
90. Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol. 2000;142(3):582-4.
91. Edmonds EVJ, Morris SD, Short K, et al. Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone. Clin Exp Dermatol. 2005;30(6):709-10.
92. Kapoor R, Kapoor JR. Cyclosporine resolves generalized pustular psoriasis of pregnancy. Arch Dermatol. 2006;142(10):1373-5.
93. Kura MM, Surjushe AU. Generalized pustular psoriasis of pregnancy treated with oral cyclosporine. Indian J Dermatol Venereol Leprol. 2006;72(6):458-9.
94. Hazarika D. Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine. Indian J Dermatol Venereol Leprol. 2009;75(6):638.
95. Wright S, Glover M, Baker H. Psoriasis, cyclosporine, pregnancy. Arch Dermatol. 1991;127(3):426.
96. Raychaudhuri SP, Navare T, Gross J, et al. Clinical course of psoriasis during pregnancy. Int J Dermatol. 2003;42(7):518-20.
97. ® Pregnancy Registry for Psoriasis and Rheumatoid Arthritis. http://npr.giftoflifeinstitute.org. Accessed 26 Feb 2013.
98. Biggioggero M, Borghi MO, Gerosa M, et al. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus. 2007;16(8):651-6.
99. Manger K, Kalden JR, Manger B. Cyclosporine A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol. 1996;35(7):669-75.
100. Doria A, Di Leonardo L, Vario S, et al. Cyclosporine A in a pregnant patient affected with systemic lupus erythematosus. Rheumatol Int. 1992;12(2):77-8.
101. Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol. 1993;40(3):160-3.
102. Maeshima E, Yamada Y, Kodama N, et al. Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporine A. Scand J Rheumatol. 1999;28(1):54-7.
103. Airo P, Antonioli CM, Motta M, Faden D, Chirico G, et al. The immune development in a child born to a cyclosporine A-treated woman with systemic lupus erythematosus/polymyositis. Lupus. 2002;11(7):454-7.
104. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004;270(2):79-85 (Epub 2003 Apr 30).
105. Angelberger S, Reinisch W, Dejaco C. Prevention of abortion by cyclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut. 2006;55(9):1364-5.
106. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103(5):1203-9.
107. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99(4):656-61.
108. Reindl W, Schmid RM, Huber W. Cyclosporine A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut. 2007;56(7):1019.
109. Bertschinger P, Himmelmann A, Risti B, et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90(2):330.
110. Jayaprakash A, Gould S, Lim AG, et al. Use of cyclosporine in pregnancy. Gut. 2004;53(9):1386-7.
111. Modigliani R. Drug therapy for ulcerative colitis during pregnancy. Eur J Gastroenterol Hepatol. 1997;9(9):854-7.
112. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16(5):881-95.
113. Cassina M, Fabris L, Okolicsanyi L, et al. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opin Drug Saf. 2009;8(6):695-707.
114. Chaparro M, Gisbert J. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol. 2011;12(5):765-73.
115. Tandon VR, Sharma S, Mahajan A, et al. Pregnancy and rheumatoid arthritis. Indian J Med Sci. 2006;60(8):334-44.
116. Choudhry VP, Gupta S, Gupta M, et al. Pregnancy associated aplastic anemia: a series of 10 cases with review of literature. Hematology. 2002;7(4):233-8.
117. Ohba T, Yoshimura T, Araki M, et al. Aplastic anemia in pregnancy: treatment with cyclosporine and granulocyte-colony stimulating factor. Acta Obstet Gynecol Scand. 1999;78(5):458-61.
118. Imai N, Watanabe R, Fujiwara H, et al. Successful treatment of impetigo herpetiformis with oral cyclosporine during pregnancy. Arch Dermatol. 2002;138(1):128-9.
119. Brightman L, Stefanato CM, Bhawan J, et al. Third-trimester impetigo herpetiformis treated with cyclosporine. J Am Acad Dermatol. 2007;56(2 Suppl):S62-4.
120. Basso M, Ghio M, Filaci G, Setti M, Indiveri F. A case of successful pregnancy in a woman with systemic sclerosis treated with cyclosporine. Rheumatology. 2004;43(10):1310-1.
121. Yamaguchi K, Yamamoto A, Hisano M, Natori M, Murashima A. Herpes simplex virus 2-associated hemophagocytic lymphohistiocytosis in a pregnant patient. Obstet Gynecol. 2005;105(5 Pt 2):1241-4.